News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Led by Former Eli Lilly (LLY) Exec, Apexian Out to Tackle Pancreatic Cancer



11/16/2016 6:24:24 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Pancreatic cancer’s standard of care includes a drug that does not help most people diagnosed with the disease. Gemcitabine (Gemzar) works in only about 10 percent of patients, says Steve Carchedi, CEO of Apexian Pharmaceuticals.

Carchedi knows about gemcitabine’s limitations because he worked at Eli Lilly (NYSE: LLY) when the FDA approved the Indianapolis-based company’s drug in 1996 to treat pancreatic cancer.

Read at Xconomy


comments powered by Disqus
Xconomy
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES